NCT05772169 - Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST) | Biotech Hunter

Enrollment

1,113

Participants

Timeline

Start Date

March 31, 2023

Primary Completion Date

November 19, 2024

Study Completion Date

December 18, 2024

Conditions

HypercortisolismDiabetes Mellitus, Type 2

Interventions

DRUG

Mifepristone 300 MG [Korlym]

Mifepristone tablets for once daily oral dosing

DRUG

Placebo for mifepristone

Placebo tablets for once daily oral dosing

Trial Locations (36)

11787

Site 411, Smithtown

12208

Site 070, Albany

20782

Site 394, Hyattsville

21239

Site 410, Baltimore

27514

Site 181, Chapel Hill

28401

Site 059, Wilmington

30303

Site 009, Atlanta

30318

Site 097, Atlanta

32132

Site 444, Edgewater

33312

Site 015, Fort Lauderdale

41011

Site 046, Covington

43210

Site 077, Columbus

43215

Site 195, Columbus

44195

Site 042, Cleveland

45219

Site 436, Cincinnati

48109

Site 074, Ann Arbor

70006

Site 061, Metairie

70112

Site 377, New Orleans

70121

Site 205, New Orleans

75230

Site 370, Dallas

75904

Site 408, Lufkin

78207

Site 054, San Antonio

78229

Site 369, San Antonio

78613

Site 456, Cedar Park

89128

Site 371, Las Vegas

90057

Site 373, Los Angeles

90247

Site 379, Gardena

90255

Site 378, Huntington Park

90502

Site 375, Torrance

91356

Site 387, Tarzana

92025

Site 407, Escondido

92037

Site 406, La Jolla

97239

Site 049, Portland

97527

Site 435, Grants Pass

98108

Site 405, Seattle

02115

Site 067, Boston